Related Experiment Videos

Natriuretic peptide measurement as a screening test for overt and subclinical heart failure

Motoyuki Nakamura1, Katsuhiko Hiramori

  • 1Second Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan. nkmrmoto@iwate-med.ac.jp

International Journal of Cardiology
|November 7, 2003
PubMed

Insights

Plasma natriuretic peptide tests can help identify heart failure early. Measuring these peptides offers a promising approach for mass screening of cardiac conditions.

Area of Science:

  • Cardiology
  • Biomarkers
  • Diagnostic Medicine

Background:

  • Heart failure prevalence is rising globally, particularly in aging populations.
  • Current diagnostic methods like chest X-rays and echocardiography are insufficient for large-scale screening.
  • Improved early detection of cardiac disease is crucial for better heart failure prognosis.

Purpose of the Study:

  • To review the utility of plasma natriuretic peptide measurements for identifying patients with heart failure.
  • To assess the role of natriuretic peptides in detecting left ventricular dysfunction and high-risk individuals.
  • To evaluate the effectiveness of natriuretic peptides in mass screening settings for cardiac conditions.

Main Methods:

  • Review of recent studies on plasma natriuretic peptide measurement.
  • Focus on B-type natriuretic peptide (BNP) due to its stability and ease of measurement.
  • Analysis of natriuretic peptide levels in relation to cardiac abnormalities and ventricular function.

Main Results:

  • Natriuretic peptides are elevated in various structural heart diseases, irrespective of cause or systolic dysfunction.
  • B-type natriuretic peptide is a stable biomarker measurable without complex procedures.
  • Plasma natriuretic peptide levels correlate with cardiac abnormalities like ventricular dysfunction, overload, hypertrophy, and ischemia.

Conclusions:

  • Plasma natriuretic peptide measurement is a valuable tool for identifying patients with congestive heart failure.
  • This biomarker aids in detecting left ventricular dysfunction and individuals at high risk for heart failure.
  • Natriuretic peptide testing shows significant potential for mass screening applications in cardiology.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...